Company / R&D per Share
Akebia Therapeutics, Inc. R&D per Share History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.28
FY2025
5-year range
$0.19 / $2.18
FY2021-FY2025
Trend
+43.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share returned to growth in FY2025 after 4 years of decline, reaching $0.28.
Based on SEC 10-K filings.
0.28 in FY2025 with a 10-year CAGR of -4.4%.
Declined from $0.34 to $0.28 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -27.7%
- 5-Year CAGR
- -35.0%
- 10-Year CAGR
- -4.4%
Key checks
Key Insights
- In FY2025, r&d per share increased 43.3% year-over-year.
- Peak r&d per share was recorded in FY2014.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.28 | +43.3% |
| FY2024 | $0.19 | -43.5% |
| FY2023 | $0.34 | -53.4% |
| FY2022 | $0.73 | -66.3% |
| FY2021 | $2.18 | -8.8% |
| FY2020 | $2.39 | +21.1% |
| FY2019 | $1.98 | -18.8% |
| FY2018 | $2.43 | +456.5% |
| FY2015 | $0.44 | -89.3% |
| FY2014 | $4.07 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026